Follow Us

       


"Like" us on Facebook

Clinical Trials

Disease or Condition
Cancer - Breast Cancer
Title
Breast Cancer - Novartis (TRIO)
Description
A phase III randomized, double blind placebo controlled study of BKM120 with fulvestrant, in postmenopausal women with hormone receptor-positive HER2-negative locally advanced or metastatic breast cancer which progressed on or after aromatase inhibitor treatment
IRB Number
NCT01610284
Inclusion/Notes
For more information, please click here: http://www.clinicaltrials.gov/ct2/show/NCT01610284?term=NCT01610284&rank=1
Status
Closed to Enrollment
Principal Investigator
Frederic C. Kass, MD
Contact Email
research@ccsb.org
Phone
(805) 898-2117

This is the fat footer - edit page 906 to add content.